RECRUITING

Cold Atmospheric Plasma Device Extension Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one year, depending on lesion clearance. The number of lesions will be chosen by the dermatologist. Patients who opt to participate will receive non-thermal, or cold, atmospheric plasma to treat all lesions selected. Safety profile as well as changes in size, pain and appearance will be measured. Photographs and dermatologist impressions will be used to measure treatment response.

Official Title

Cold Atmospheric Plasma Device for the Treatment of Molluscum Contagiosum and Verruca Vulgaris in Pediatric Patients - Open-Label Extension Study

Quick Facts

Study Start:2023-09-18
Study Completion:2025-07-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05937672

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:4 Years to 21 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * All patients from 4-21 years old with at least 1 lesion of vercurra or molluscum.
  2. * Willingness of the participant and their guardian to provide consent when applicable.
  1. * Unwillingness to participate in the study
  2. * Received any treatment on the lesion in the past month determined by review of their medical record
  3. * Immunodeficiency determined by review of their medical record.
  4. * Adverse response to prior treatments determined by review of medical record.
  5. * Signs of self-resolution determined by study team members.
  6. * Conditions that lead to excessive scarring determined by study team members.
  7. * Face and genital lesions determined by study team members.

Contacts and Locations

Study Contact

Courtney Linkous, BA
CONTACT
843-566-2453
linkousc@musc.edu
Courtney Rowley
CONTACT
843-792-4349
rowle@musc.edu

Study Locations (Sites)

Medical University of South Carolina
Charleston, South Carolina, 29425
United States

Collaborators and Investigators

Sponsor: Medical University of South Carolina

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-18
Study Completion Date2025-07-01

Study Record Updates

Study Start Date2023-09-18
Study Completion Date2025-07-01

Terms related to this study

Keywords Provided by Researchers

  • Plasma
  • Warts
  • Molluscum
  • Pediatric
  • Dermatology

Additional Relevant MeSH Terms

  • Verruca Vulgaris
  • Molluscum Contagiosum